相关实验视频
Updated: Jul 11, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
药剂师护理在糖尿病管理中的成本效益:系统性审查
Jiejin Zhu1, Ying Zhou1, Gang Wang2
1Department of Clinical Pharmacy, Hangzhou First People's Hospital, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.
概括
药剂师参与糖尿病管理是具有成本效益的,导致更好的血糖控制和减少药物问题. 需要进一步进行高质量的研究,以改善医疗保健决策报告标准.
科学领域:
- 卫生经济学 卫生经济学
- 药房实践 在药房实践中
- 糖尿病管理 糖尿病管理
背景情况:
- 药剂师的作用已经演变为以患者为中心的护理和慢性疾病管理.
- 药剂师参与糖尿病管理的成本效益需要进一步研究.
研究的目的:
- 与标准护理相比,系统地审查药剂师主导的糖尿病管理的成本效益.
- 评估该领域经济评估的报告质量.
主要方法:
- 对糖尿病中药剂师干预措施的成本效益分析的系统审查.
- 搜索了多个数据库 (PubMed,Scopus,CNKI,HT A) 到2023年7月.
- 通过两个独立审稿人的CHEERS 2022检查清单评估研究质量.
主要成果:
- 包括12项研究,只有4项被评为高质量.
- 药剂师参与糖尿病管理一直被认为是具有成本效益或节省成本的.
- 益处包括改善血糖控制,提高患者的遵从性,减少与药物相关的问题.
结论:
- 与标准护理相比,药剂师参与糖尿病管理具有成本效益.
- 需要提高经济评估报告的质量.
- 高质量的证据对于明智的医疗保健和药房实践决策至关重要.
相关概念视频
Diabetes: Management and Pharmacotherapy
290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
Insulin: Dosing Regimen and Adverse Effects
184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184
Peripheral Artery Disease IV: Nursing Management
11
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
11
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212

